Senari Pharma is a seed-stage pharma company targeting a $2bn market through the development of an inhaled therapeutic for obstructive lung disease using known molecules in a novel way. The company is raising $20M to fund progress through to Phase 1 and 2 clinical trials with a view to a potential exit prior to Phase 3. Senari's product will be differentiated through its unique formulation in order to resonate with prescribers and opinion leaders. The company is reducing the risk of formulation development and time to market through leveraging well-established inactive ingredients and device components and aims to initiate Phase 1 in Q4 2021. Senari is led by Dr Sanjeeva Dissanayake, CEO and Founder, who has 20 years' experience in the pharmaceutical industry that includes five major multinational regulatory approvals. The management team is completed by two senior pharmaceutical executives: Dr Anne Brindley, a recognised industry expert in inhaled product development with a central role in the approval of two major inhaled product brands; and Peter McGowan a high calibre and commercially astute CFO with 30 years of pharma experience in both start up and established organisations.
Senari Pharma is a seed-stage pharma company targeting a $2bn market through the development of an inhaled therapeutic for obstructive lung disease using known molecules in a novel way. The company is raising $20M to fund progress through to Phase 1 and 2 clinical trials with a view to a potential exit prior to Phase 3. Senari's product will be differentiated through its unique formulation in order to resonate with prescribers and opinion leaders. The company is reducing the risk of formulation development and time to market through leveraging well-established inactive ingredients and device components and aims to initiate Phase 1 in Q4 2021. Senari is led by Dr Sanjeeva Dissanayake, CEO and Founder, who has 20 years' experience in the pharmaceutical industry that includes five major multinational regulatory approvals. The management team is completed by two senior pharmaceutical executives: Dr Anne Brindley, a recognised industry expert in inhaled product development with a central role in the approval of two major inhaled product brands; and Peter McGowan a high calibre and commercially astute CFO with 30 years of pharma experience in both start up and established organisations.
Agree soup just reading the updated Allenby report and it states
Current development activities
Nuformix has sourced supplies of NXP002 for use in formulation development activities, for nebulisation feasibility studies and in vivo studies. It is conducting preclinical pharmacokinetic and pharmacodynamic studies in relevant in vivo models that are designed to demonstrate that NXP002 has appropriate properties for use as an inhaled therapy for IPF. These studies, once complete, will collectively form an inhalation feasibility package. This work will then shift towards development of a liquid formulation suitable for use with a nebuliser with desirable pH, osmolarity etc so that it can be used safely in patients, and other characteristics so that an aerosol has the right droplet size for accurate and consistent delivery to the lung. Once completed, Nuformix could use an off- the-shelf nebuliser to test a product and/or engage with a developer of a more specialised nebuliser (e.g. Monaghan Medical, Vectura, Phillips, Omron or Pari International).
Nuformix has not published any of its work to date, in part for reasons of commercial sensitivity. However, a paper published last year by Japanese academic researchers (Kato et al) provides some independent scientific support to the project. The authors reported the results of a study investigating in vitro effects of tranilast on extracellular matrix production and the TGFß/SMAD2 pathway in human alveolar epithelial cells, with in vitro observations validated in a murine pulmonary fibrosis model. The authors concluded that tranilast is a promising and novel anti-fibrotic agent for IPF.
Timelines for NXP002
Nuformix expects to complete the development of the liquid formulation by the end of this year, by which point it will be able to conduct non-GLP toxicology studies of the inhaled product, which will be required for the change of route of administration. This will be in two different species. On completion of these studies, towards the end of 2022, it should be in a good position to seek a licensing deal, although it is possible this could be achieved earlier.
So to manage expectations I’m not expecting anything sooner although it does state this could be a possibility. The other point I noticed was
“Nuformix is likely to seek ODD status for tranilast for IPF in due course” obviously funding permitting!!
There was this back in June
Repsol Sinopec extends lease for North Sea FPSO
PROJECT & TENDERS
June 28, 2021, by Nermina Kulovic
Repsol Sinopec Resources, together with its JV partner RockRose Energy, has awarded an extension of the bareboat charter to the Bluewater-owned FPSO Bleo Holm.
The new contract term will run until 31 December 2024 and thereafter Repsol Sinopec may take out further one-year extensions at its discretion, the company said last Friday.
The Bleo Holm FPSO is owned by Bluewater and operated by Repsol Sinopec. The FPSO is located in the North Sea in UKCS Block 13/28a on the Blake and Ross fields, 72 miles northeast of Aberdeen, since 1999. The fields are operated by Repsol Sinopec with RockRose as its partner.
Back in March 2018, RockRose commissioned two reports, one to evaluate the potential of the Blake field and Tain discovery, and another one to review the FPSO options on the Blake & Ross fields. The scope of the FPSO report was looking at replacing the current vessel or extending the life of the Bleo Holm, with the vessel currently targeted to be on station until 2024.
This was undertaken with a view to extending the life of the fields and giving the opportunity to fully deliver other discovered hydrocarbons in the area.
The Tain development is expected to be produced over the Bleo Holm FPSO as part of the life of field extension. In early 2020, Repsol Sinopec released an Environmental Statement for public consultation on the proposed development of the Tain field, Licence P.983.
The recommended development concept includes two deviated production wells, with production routed to the Bleo Holm FPSO via a new 19 km pipeline with associated gas lift line and control/chemical injection umbilical.
José Luis Muñoz, Repsol Sinopec CEO said: “I am very pleased that this lease has been extended. In alignment with the Oil & Gas Authority’s MER UK Strategy this is a clear demonstration of our commitment to the North Sea and is a timely development to encourage further investment, increase production and facilitate life extension for the area, all while remaining focussed on emissions reduction opportunities”.
Hugo Heerema, CEO of Bluewater, said: “We are pleased to have been part of making serious additional life of field possible, in what we see as a win-win for ourselves and our client”.
The FPSO is based on a purpose build tanker monohull, which was constructed at Hitachi Yard in Japan. The vessel has a double hull, double sides, double bottom, a bulbous bow and weighs 105,000 deadweight tonnes.
https://www.offshore-energy.biz/repsol-sinopec-extends-lease-for-north-sea-fpso/
Visualization and analytical solutions developer Imaging Biometrics released a new version of its IB Software, including a new parameter map within IB Neuro “percent signal recovery” (PSR) and improved appearance of all output maps. The company was also awarded a patent for IB Zero G – an AI technology that eliminates the need for gadolinium based contrast agents (GBCAs) on MRI exams.
https://www.blackfordanalysis.com/2021/07/01/partner-highlights-june-2021/
Joke company now too many shares in issue!! When I first invested here it was about 60m ish in issue (from memory) now well over a billion and plenty more to come good luck LTH!!
Very personal investor friendly to announce on a Friday when market is shut!! This bunch of crooks won’t change they will always dangle the carrot then hit you with the stick!!! They knew exactly how the market would react hence they’ve left it until tonight to announce!!
AVOID!!!
It’s from a proactive news article from September here’s the link
HC Wainwright analyst Raghuram Selvaraju also used his updated research note to assess the demerger of Accustem Sciences, which was confirmed last week, and to re-affirm his US$280mln valuation of the StemPrintER diagnostic being spun off with it.
“This would imply that the value of StemPrintER could be considered close to the entire current market cap of Tiziana, meaning that Tiziana's current pipeline of drug candidates is being assigned only nominal value,” said the analyst.
“This still provides a compelling incentive to consider an investment in Tiziana shares, in our view.”
Accustem is being floated off with the breast cancer diagnostic StemPrintER and the SPARE genomics-based personalised medicine business plus cash reserves of around £1mln.
StemPrintER is the jewel in the crown and was recently shown to outperform the best-in-class technology that was sold as part of a deal worth US$2.8bn last year, Selvaraju pointed.
https://www.proactiveinvestors.co.uk/companies/news/929555/tiziana-life-sciences-hc-wainwright-sees-meaningful-upside-to-price-target-if-foralumab-covid-19-trial-is-a-success-929555.html
Noticed this document whilst looking at
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2020035546&tab=PCTDOCUMENTS
International application status report
Report generated on: 05 July 2021 (05.07.2021)
https://patentscope.wipo.int/search/docs2/iasr/WO2020035546/html/UBfbHOetLtJLKmNT_wn9q211MFgCEzc1Hr9V9ghs43PllBeOhfD9ZgUjJXqkS0HlSAbXwPyEpQQKOHCDLgk6Y2BwsbjBahjgR86FFDvWq1THq4aUSQ3J3_lX-iYMuCZd
Is this just generic? Any perticular reason the report was genarated today?
Repsol Sinopec extends lease for North Sea FPSO
PROJECT & TENDERS
June 28, 2021, by Nermina Kulovic
Repsol Sinopec Resources, together with its JV partner RockRose Energy, has awarded an extension of the bareboat charter to the Bluewater-owned FPSO Bleo Holm.
The new contract term will run until 31 December 2024 and thereafter Repsol Sinopec may take out further one-year extensions at its discretion, the company said last Friday.
The Bleo Holm FPSO is owned by Bluewater and operated by Repsol Sinopec. The FPSO is located in the North Sea in UKCS Block 13/28a on the Blake and Ross fields, 72 miles northeast of Aberdeen, since 1999. The fields are operated by Repsol Sinopec with RockRose as its partner.
Back in March 2018, RockRose commissioned two reports, one to evaluate the potential of the Blake field and Tain discovery, and another one to review the FPSO options on the Blake & Ross fields. The scope of the FPSO report was looking at replacing the current vessel or extending the life of the Bleo Holm, with the vessel currently targeted to be on station until 2024.
This was undertaken with a view to extending the life of the fields and giving the opportunity to fully deliver other discovered hydrocarbons in the area.
The Tain development is expected to be produced over the Bleo Holm FPSO as part of the life of field extension. In early 2020, Repsol Sinopec released an Environmental Statement for public consultation on the proposed development of the Tain field, Licence P.983.
The recommended development concept includes two deviated production wells, with production routed to the Bleo Holm FPSO via a new 19 km pipeline with associated gas lift line and control/chemical injection umbilical.
José Luis Muñoz, Repsol Sinopec CEO said: “I am very pleased that this lease has been extended. In alignment with the Oil & Gas Authority’s MER UK Strategy this is a clear demonstration of our commitment to the North Sea and is a timely development to encourage further investment, increase production and facilitate life extension for the area, all while remaining focussed on emissions reduction opportunities”.
https://www.offshore-energy.biz/repsol-sinopec-extends-lease-for-north-sea-fpso/
They do have authority to buy back shares it’s in last year’s annual general meeting notice under special resolutions
SPECIAL RESOLUTIONS
7. THAT, conditional on the passing of Resolution 6 above and in addition to all existing authorities, the Directors be and are hereby generally and unconditionally authorised pursuant to sections 570 and 573 of the Act to make allotments of equity securities (within the meaning of section 560 of the Act) for cash pursuant to the authority conferred by Resolution 6 as if section 561 of the Act did not apply to any such allotment, provided that such power shall be limited to the allotment of equity securities:
a. in the case of paragraph (a) of Resolution 6: (i) in connection with a pre-emptive offer and (ii) otherwise than in connection with a pre-emptive offer, up to an aggregate nominal amount of £3,590 (representing approximately one-third of the issued ordinary share capital of the Company); and
b. in the case of paragraph (b) of Resolution 6, in connection with a rights issue,
provided that such authority will expire at the same time as the authority granted pursuant to the passing of Resolution 6, save that the Company may before such expiry make an offer or agreement which would or might require equity securities to be allotted after such expiry date and the Directors may allot equity securities in pursuance of such offer or agreement notwithstanding that the power conferred by this resolution had expired.
8. THAT the Company be generally and unconditionally authorized for the purpose of Section 701 of the Act to make market purchases (within the meaning of Section 693(4) of the Act) of fully-paid Ordinary Shares on such terms and in such manner as the Directors may decide, provided that:
a. the maximum number of Ordinary Shares that may be purchased pursuant to this authority is 10,771,940, representing approximately one-tenth of the Company’s issued Ordinary Share capital as at 3 June 2020;
b. the minimum price that may be paid for any such Ordinary Share shall be the nominal value of that Ordinary Share (exclusive of expenses payable by the Company in connection with the purchase) at the time of purchase;
c. the maximum price, exclusive of any expenses, which may be paid for each Ordinary Share is an amount equal to the higher of: (i) 105% of the average market value of an Ordinary Share, as derived from the London Stock Exchange Daily Official List for the five business days prior to the day on which the purchase is made; and (ii) an amount equal to the higher of the price of the last independent trade of an Ordinary Share and the highest current independent bid for an Ordinary Share as derived from the London Stock Exchange Trading System
https://i3.energy/wp-content/uploads/2020/06/i3-NOTICE-OF-AGM-30-June-2020.pdf